CPT: 82947
Test #: 001032


Blood Sugar

Expected Turnaround Time

24 Hours

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

Specimen Requirements


Serum, Plasma


SST (Serum), Red Top (Separate Serum), Lithium Heparin (Plasma), EDTA (Plasma)

Storage Instructions

Room Temp., Refrigerated (2-8 C)

Stability Requirements

Room temp. 72hrs., Refrigerated 7 days

Patient Preparation

Blood should be drawn in the morning after an overnight fast. Per the American Diabetes Association (ADA), fasting is defined as no caloric intake for at least eight hours.<sup1</sup>

Causes for Rejection

Samples unspun or improperly spun (excluding oxalate/NaF); gross hemolysis; gross bacterial contamination; improper labeling

Test Details


Diagnose diabetes mellitus; evaluate disorders of carbohydrate metabolism including alcoholism; evaluate acidosis and ketoacidosis; evaluate dehydration, coma, hypoglycemia of insulinoma and neuroglycopenia

Additional Information

According to the ADA, a fasting glucose >125 mg/dL on more than one occasion is adequate for the diagnosis of diabetes mellitus.

The ADA further classifies an intermediate group of individuals whose glucose levels do not meet criteria for diabetes yet are higher than those considered normal. These individuals were defined as having impaired fasting glucose (IFG) in plasma between 100-125 mg/dL.<sup>1</sup>

The ADA defines three levels of hypoglycemia, with Level 1 cut-point being the most sensitive for detection.<sup>2</sup> Level 1 hypoglycemia is defined as a measurable glucose concentration <70 mg/dL but >53 mg/dL. A blood glucose concentration of 70 mg/dL has been recognized as a threshold for neuroendocrine responses to failing glucose in people with diabetes. Because many people with diabetes demonstrate impaired counterregulatory responses to hypoglycemia and/or experience hypoglycemia unawareness, a measured glucose level <70 mg/dL is considered clinically important.

Criteria for diagnosis of diabetes include<sup>2</sup>:

A1C >6.4% (utilizing NGSP certified and standardized to the DCCT assay);* or

Fasting glucose level >125 mg/dL;* or

A two-hour plasma glucose >199 mg/dL during an OGTT;* or

Classic symptoms of hyperglycemia or hyperglycemic crisis, with random plasma glucose >199 mg/dL.

*In the absence of unequivocal hyperglycemia, criteria 1-3 should be confirmed by repeat testing.

Recent evidence revealed a diurnal variation in FPG, with mean FPG higher in the morning than in the afternoon, indicating that many cases of undiagnosed diabetes would be missed in patients seen in the afternoon. Glucose concentrations decrease ex vivo with time in whole blood because of glycolysis. The rate of glycolysis, reported to average 5% to 7% [~0.6 mmol/L (10 mg/dL)] per hour, varies with the glucose concentration, temperature, white blood cell count and other factors. Glycolysis can be attenuated by inhibition of enolase with sodium fluoride (2.5 mg fluoride/mL of blood) or, less commonly, lithium iodacetate (0.5 mg/mL of blood). These reagents can be used alone or, more commonly, with anticoagulants such as potassium oxalate, EDTA, citrate or lithium heparin. Although fluoride maintains long-term glucose stability, the rate of decline of glucose in the first hour after sample collection in tubes with and without fluoride is virtually identical. (Note that leukocytosis will increase glycolysis even in the presence of fluoride if the white cell count is very high). After four hours, the glucose concentration is stable in whole blood for 72 hours at room temperature in the presence of fluoride. In separated, nonhemolyzed, sterile serum without fluoride, the glucose concentration is stable for 14 days at 25°C and 4°C.


1. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2014 Jan;37 Suppl 1:S81-S90. PubMed 24357215

2. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S73-S84. PubMed 33298417


Order Code
Order Code Name
Order Loinc
Result Code
Result Code Name
Result LOINC

Statement on Medical Necessity
All ordered tests should be medically necessary for the diagnosis or detection of disease, illness, impairment, symptom, syndrome, or disorder and the results should be used in the medical management and treatment decisions for the patient. Solaris requires ICD-10 codes with each order for lab testing and both the tests ordered and the diagnosis should be documented in the provider’s medical record for the patient. The United States Department of Health and Human Services, Office of Inspector General, takes the position that a provider who orders medically unnecessary tests may be subject to civil penalties.

Panels and Profiles
Solaris offers Providers the convenience of ordering test combinations in a group at times with the flexibility to choose appropriate test(s) for individual patients. Providers should only order those tests that he or she believes are medically necessary for each patient, and a lesser inclusive profile or individual tests should be ordered if not all tests in the test combination/profile are medically necessary. All tests offered in a test combination/profile may be ordered separately as individual tests. Solaris encourages clients to contact their Solaris representative if the testing configurations shown do not meet individual needs for any reason, or if some other combination of procedures is needed.

CPT Codes
CPT Codes listed are in accordance with Current Procedural Terminology, a publication of the American Medical Association. CPT codes are the responsibility of the billing party and are listed here for informational purposes. Correct coding may vary from one carrier to another. Solaris may bill specific carriers using codes other than what is shown.


For questions or inquiries related to testing please reach out to or contact us by phone at (844) 550-0308.